Chemistry:5-MAPB

From HandWiki
Short description: Chemical compound
5-MAPB
5-MAPB.svg
Ball-and-stick model of 5-MAPB molecule
Clinical data
Routes of
administration
Oral, Insufflated, Rectal
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC12H15NO
Molar mass189.25 g/mol (freebase)
225.7 g/mol (HCl salt) g·mol−1
3D model (JSmol)

5-MAPB (1-(benzofuran-5-yl)-N-methylpropan-2-amine) is an entactogenic designer drug similar to MDMA in its structure and effects.[1]

Legal Status

Canada

5-MAPB is not listed itself in the CDSA but since it is structurally related to MDMA it may be considered illegal in Canada, although this has not been tested in court.[2]

China

As of October 2015 5-MAPB is a controlled substance in China.[3]

Luxembourg

As of July 2021, 5-MAPB is not cited in the list of prohibited substances.[4] Therefore, it is still a legal substance.

United Kingdom

5-MAPB was originally banned in the UK in June 2013 under a Temporary class drug order.[5] On March 5, 2014, the UK Home Office announced that 5-MAPB would be made a class B drug on 10 June 2014 alongside every other benzofuran entactogen and many structurally related drugs.[6]

Pharmacokinetics

Metabolism and toxicity

Little formal knowledge exists on 5-MAPB. It does not form the alpha-methyldopamine metabolite that contributes to the neurotoxicity of MDMA or MDA.[7][8][9] A study in rats indicated that the major metabolites of 5-MAPB are 5-APB and 3-carboxymethyl-4-hydroxymethamphetamine.[10]

Pharmacodynamics

5-MAPB binds to the dopamine transporter in rat brain cells with a lower affinity than cocaine. In silico data suggests that the primary action on dopamine is through reversal of the transporter to release dopamine. This is consistent with the effects and it is possible that it exerts a similar action on serotonin and norepinephrine transporters.[11]

References

  1. "Temporary class drug order report on 5-6APB and NBOMe compounds". UK Home Office. 4 Jun 2013. https://www.gov.uk/government/publications/temporary-class-drug-order-report-on-benzofury-and-nbome-compounds. 
  2. "Schedule I". Government Of Canada. 2014-12-12. http://laws-lois.justice.gc.ca/eng/acts/c-38.8/page-24.html#h-28. 
  3. "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. http://www.sfda.gov.cn/WS01/CL0056/130753.html. 
  4. Loi du 19 février 1973 concernant la vente de substances médicamenteuses et la lutte contre la toxicomanie. | http://legilux.public.lu/eli/etat/leg/loi/1973/02/19/n1/jo
  5. "'NBOMe' and 'Benzofury' banned". UK Home Office. 2013-06-04. https://www.gov.uk/government/news/nbome-and-benzofury-to-be-banned. 
  6. UK Home Office (2014-03-05). "The Misuse of Drugs Act 1971 (Ketamine etc.) (Amendment) Order 2014". UK Government. http://www.legislation.gov.uk/ukdsi/2014/9780111110904. 
  7. "Major metabolites of (+/-)3,4-methylenedioxyamphetamine (MDA) do not mediate its toxic effects on brain serotonin neurons". Brain Research 545 (1–2): 279–82. April 1991. doi:10.1016/0006-8993(91)91297-E. PMID 1860050. 
  8. "2,5-Bis-(glutathion-S-yl)-alpha-methyldopamine, a putative metabolite of (+/-)-3,4-methylenedioxyamphetamine, decreases brain serotonin concentrations". European Journal of Pharmacology 323 (2–3): 173–80. April 1997. doi:10.1016/S0014-2999(97)00044-7. PMID 9128836. 
  9. "Acute and chronic administration of alpha-methyldopa: regional levels of endogenous and alpha-methylated catecholamines in rat brain". European Journal of Pharmacology 52 (3–4): 271–80. December 1978. doi:10.1016/0014-2999(78)90279-0. PMID 729639. 
  10. "Benzofuran analogues of amphetamine and methamphetamine: studies on the metabolism and toxicological analysis of 5-APB and 5-MAPB in urine and plasma using GC-MS and LC-(HR)-MS(n) techniques". Analytical and Bioanalytical Chemistry 407 (5): 1371–88. February 2015. doi:10.1007/s00216-014-8360-0. PMID 25471293. 
  11. "Combined in vitro and in silico approaches to the assessment of stimulant properties of novel psychoactive substances - The case of the benzofuran 5-MAPB". Progress in Neuro-Psychopharmacology & Biological Psychiatry 75: 1–9. April 2017. doi:10.1016/j.pnpbp.2016.11.004. PMID 27890676. http://clok.uclan.ac.uk/16476/1/Davidson%205MAPB.pdf.